Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer

Prostate

Volumn 76, Issue 1, 2016, Pages 97-113

  Corbin, Joshua M ^a   Overcash, Ryan F ^b   Wren, Jonathan D ^c   Coburn, Anita ^d   Tipton, Greg J ^e   Ezzell, Jennifer A ^e   McNaughton, Kirk K ^e   Fung, Kar Ming ^a,f   Kosanke, Stanley D ^a   Ruiz Echevarria, Maria J ^a,g  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d EAST CAROLINA UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Stephenson Cancer Center   (United States)

Author keywords

branching morphogenesis; neuroendocrine tumors; prostate cancer; TMEFF2; transgenic mouse

Indexed keywords

MEMBRANE PROTEIN; TRANSMEMBRANE PROTEIN WITH EPIDERMAL GROWTH FACTOR AND TWO FOLLISTATIN MOTIFS 2 PROTEIN; UNCLASSIFIED DRUG; TMEFF2 PROTEIN, MOUSE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; METABOLOMICS; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE REGENERATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE REGENERATION; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL TRANSFORMATION; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROENDOCRINE TUMOR; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REGENERATION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEUROENDOCRINE TUMORS; PROSTATE; PROSTATIC NEOPLASMS; REGENERATION; TUMOR CELLS, CULTURED;

EID: 84955177290     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23103     Document Type: Article

References (51)

1. Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, Kasuga M, Sakamoto C,. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999; 266 (2): 593-602.
2. Heanue TA, Pachnis V,. Expression profiling the developing mammalian enteric nervous system identifies marker and candidate Hirschsprung disease genes. Proc Natl Acad Sci USA 2006; 103 (18): 6919-6924.
3. Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, Taylor KM, Gee JM, Nicholson RI,. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001; 94 (2): 178-184.
4. Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP,. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002; 21 (31): 4739-4746.
5. Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA,. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 2004; 3 (8): 921-932.
6. Eib DW, Holling TM, Zwijsen A, Dewulf N, de Groot E, van den Eijnden-van Raaij AJ, Martens D,. Expression of the follistatin/EGF-containing transmembrane protein M7365 (tomoregulin-1) during mouse development. Mech Dev 2000; 97 (1-2): 167-171.
7. Morais da Silva S, Gates PB, Eib DW, Martens GJ, Brockes JP,. The expression pattern of tomoregulin-1 in urodele limb regeneration and mouse limb development. Mech Dev 2001; 104 (1-2): 125-128.
8. Chang C, Eggen BJ, Weinstein DC, Brivanlou AH,. Regulation of nodal and BMP signaling by tomoregulin-1 (X7365) through novel mechanisms. Dev Biol 2003; 255 (1): 1-11.
9. Harms PW, Chang C,. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. Genes Dev 2003; 17 (21): 2624-2629.
10. Markholt S, Grondahl ML, Ernst EH, Andersen CY, Ernst E, Lykke-Hartmann K,. Global gene analysis of oocytes from early stages in human folliculogenesis shows high expression of novel genes in reproduction. Mol Hum Reprod 2012; 18 (2): 96-110.
11. Kanemoto N, Horie M, Omori K, Nishino N, Kondo M, Noguchi K, Tanigami A,. Expression of TMEFF1 mRNA in the mouse central nervous system: Precise examination and comparative studies of TMEFF1 and TMEFF2. Brain Res Mol Brain Res 2001; 86 (1-2): 48-55.
12. Chen TR, Wang P, Carroll LK, Zhang YJ, Han BX, Wang F,. Generation and characterization of Tmeff2 mutant mice. Biochem Biophys Res Commun 2012; 425 (2): 189-194.
13. Gery S, Yin D, Xie D, Black KL, Koeffler HP,. TMEFF1 and brain tumors. Oncogene 2003; 22 (18): 2723-2727.
14. Wu X, Blanck A, Norstedt G, Sahlin L, Flores-Morales A,. Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium. Mol Hum Reprod 2002; 8 (3): 246-254.
15. Lin K, Taylor JR Jr., Wu TD, Gutierrez J, Elliott JM, Vernes JM, Koeppen H, Phillips HS, de Sauvage FJ, Meng YG,. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PloS ONE 2011; 6 (4): e18608.
16. Sun T, Du W, Xiong H, Yu Y, Weng Y, Ren L, Zhao H, Wang Y, Chen Y, Xu J, Xiang Y, Qin W, Cao W, Zou W, Chen H, Hong J, Fang JY,. TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. Clin Cancer Res 2014; 20 (17): 4689-4704.
17. Sun TT, Tang JY, Du W, Zhao HJ, Zhao G, Yang SL, Chen HY, Hong J, Fang JY,. Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. Int J Cancer 2015; 136 (5): 1053-1064.
18. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel EP, Minna JD, Fujisawa T, Gazdar AF,. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 2005; 93 (9): 1029-1037.
19. Brucher BL, Geddert H, Langner C, Hofler H, Fink U, Siewert JR, Sarbia M,. Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel. Int J Cancer 2006; 119 (6): 1298-1302.
20. Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, Drew PA,. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep 2009; 21 (4): 1067-1073.
21. Gonzalo V, Lozano JJ, Munoz J, Balaguer F, Pellise M, Rodriguez de Miguel C, Andreu M, Jover R, Llor X, Giraldez MD, Ocana T, Serradesanferm A, Alonso-Espinaco V, Jimeno M, Cuatrecasas M, Sendino O, Castellvi-Bel S, Castells A,. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PloS ONE 2010; 5 (1): e8777.
22. Zhang C, Zhao H, Li J, Liu H, Wang F, Wei Y, Su J, Zhang D, Liu T, Zhang Y,. The identification of specific methylation patterns across different cancers. PloS ONE 2015; 10 (3): e0120361.
23. Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, Okamoto T, Kondo M, Mori T, Noguchi K, Nakamura Y, Takahashi E, Tanigami A,. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics 2000; 67 (2): 146-152.
24. Ali N, Knauper V,. Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. J Biol Chem 2007; 282 (52): 37378-37388.
25. Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarria MJ,. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chem 2011; 286 (18): 16091-16100.
26. Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D,. HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int J Cancer 2008; 122 (7): 1567-1572.
27. Green T, Chen X, Ryan S, Asch AS, Ruiz-Echevarria MJ,. TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate 2013; 73 (14): 1561-1575.
28. Chen X, Corbin JM, Tipton GJ, Yang LV, Asch AS, Ruiz-Echevarria MJ,. The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells. Biochim Biophys Acta 2014; 1843 (6): 1216-1224.
29. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92 (8): 3439-3443.
30. Huss WJ, Maddison LA, Greenberg NM,. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001; 11 (3): 245-260.
31. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57 (16): 3325-3330.
32. Debnath J, Muthuswamy SK, Brugge JS,. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30 (3): 256-268.
33. Wren JD,. A global meta-analysis of microarray expression data to predict unknown gene functions and estimate the literature-data divide. Bioinformatics 2009; 25 (13): 1694-1701.
34. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, Matusik RJ,. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994; 8 (2): 230-239.
35. Zhang J, Thomas TZ, Kasper S, Matusik RJ,. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141 (12): 4698-4710.
36. Sugimura Y, Cunha GR, Donjacour AA,. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 1986; 34 (5): 961-971.
37. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP,. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19 (4): 348-355.
38. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A,. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172 (1): 236-246.
39. Zhang J, Wang L, Zhang Y, Lu J,. Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model. Tonissen DK, editor: InTech; 2013.
40. Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR,. Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol 2005; 42 (3): 306-314.
41. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C,. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105 (34): 12182-12187.
42. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C,. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010; 29 (25): 3593-3604.
43. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP,. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453 (7198): 1072-1078.
44. Yuan T-C, Veeramani S, Lin M-F,. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14 (3): 531-547.
45. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ,. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9 (11): 938-950.
46. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang L-S, Yang Q, Huang J,. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009; 69 (7): 787-798.
47. Castoria G, D'Amato L, Ciociola A, Giovannelli P, Giraldi T, Sepe L, Paolella G, Barone MV, Migliaccio A, Auricchio F,. Androgen-induced cell migration: role of androgen receptor/filamin A association. PloS ONE 2011; 6 (2): e17218.
48. Bryant DM, Roignot J, Datta A, Overeem AW, Kim M, Yu W, Peng X, Eastburn DJ, Ewald AJ, Werb Z, Mostov KE,. A molecular switch for the orientation of epithelial cell polarization. Dev Cell 2014; 31 (2): 171-187.
49. Plosa EJ, Young LR, Gulleman PM, Polosukhin VV, Zaynagetdinov R, Benjamin JT, Im AM, van der Meer R, Gleaves LA, Bulus N, Han W, Prince LS, Blackwell TS, Zent R,. Epithelial beta1 integrin is required for lung branching morphogenesis and alveolarization. Development 2014; 141 (24): 4751-4762.
50. Hoch RV, Soriano P,. Roles of PDGF in animal development. Development 2003; 130 (20): 4769-4784.
51. Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, isbridger RGP,. Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 2001; 237 (1): 145-158.